Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Fidelio Capital in connection with its investment in Hemfrid
Mandate

Vinge has advised Fidelio Capital in connection with its investment in Hemfrid

August 27, 2021 M&A IT, Telecommunications and Outsourcing Corporate Commercial Employment and Benefits Real Estate and Construction Intellectual Property

Vinge has advised Fidelio Capital AB in its majority investment in Hemfrid i Sverige AB, the leading player within the home service industry in Sweden, with a revenue exceeding MSEK 700 and more than 2,000 employees in 2020. The transaction is subject to customary regulatory approvals and is expected to be completed during the second half of 2021.

Vinge’s team consisted of, among others, Daniel Rosvall, Jonas Bergström, Joacim Rydergård, Filip Öhrner, Christa Anttila, Hannah Kajlinger, Annie Fällström and Amanda Steen (M&A), Karolina Fuhrman and Mika Jordan (Corporate Commercial and IT), Felizia Wiker (IPR), Gustav Lindgren and Carl Östlund (Employment), Karolina Cohrs (Real Estate), and Sara Dahlros Sköld (VDR Assistant).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025